8,800 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,800 shares of the medical instruments supplier's stock, valued at approximately $811,000.

A number of other institutional investors and hedge funds also recently modified their holdings of LMAT. Smartleaf Asset Management LLC lifted its holdings in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC boosted its holdings in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 117 shares during the period. KBC Group NV boosted its holdings in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after buying an additional 410 shares during the period. Empowered Funds LLC purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth approximately $150,000. Finally, SG Americas Securities LLC purchased a new stake in shares of LeMaitre Vascular in the 4th quarter valued at approximately $158,000. Institutional investors and hedge funds own 84.64% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on LMAT. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target on the stock. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital lifted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $95.25.

Remove Ads

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of LMAT traded down $2.06 during trading hours on Friday, hitting $79.78. 283,349 shares of the company were exchanged, compared to its average volume of 156,497. The company has a market cap of $1.80 billion, a PE ratio of 43.60, a PEG ratio of 2.22 and a beta of 0.89. The firm's 50 day moving average is $91.62 and its 200-day moving average is $94.19. LeMaitre Vascular, Inc. has a 52 week low of $62.39 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 1.00%. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular's dividend payout ratio (DPR) is currently 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.